Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. - Wikidata - awgldk - TriplyDB

Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.

Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.

http://www.wikidata.org/entity/Q35251599

about

Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.Protein binding and serum bactericidal activities of vancomycin and teicoplanin.Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots.Population pharmacokinetic study of teicoplanin in severely neutropenic patients.Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.Successful single-dose teicoplanin prophylaxis against experimental streptococcal, enterococcal, and staphylococcal aortic valve endocarditis.Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC In vivo pharmacodynamic activity of the glycopeptide dalbavancin Beta-lactams versus glycopeptides in treatment of subcutaneous abscesses infected with Staphylococcus aureus.Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon.Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.Pharmacokinetics and pharmacodynamics of antibacterial agents.Augmented renal clearance: implications for antibacterial dosing in the critically ill.Interpretation of Epithelial Lining Fluid Concentrations of Antibiotics against Methicillin Resistant Staphylococcus aureus.Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response Clinical evaluation of teicoplanin fluorescence polarization immunoassay.Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.Glycopeptides and nephrotoxicity.Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.Effect of teicoplanin on Staphylococcus aureus with heterointermediate susceptibility to glycopeptides in experimental infective endocarditis model.In vitro and in vivo characterization of a new recombinant antimicrobial peptide, MP1102, against methicillin-resistant Staphylococcus aureus.A closer look at vancomycin, teicoplanin, and antimicrobial resistance.Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis.High expression of a plectasin-derived peptide NZ2114 in Pichia pastoris and its pharmacodynamics, postantibiotic and synergy against Staphylococcus aureus.Efficacy of teicoplanin, administered in two different regimens, in the treatment of experimental endocarditis due to Enterococcus faecalis.Pharmacokinetic-pharmacodynamic model for spiramycin in staphylococcal mastitis.

P2860

Q28326763-7119CDBB-100B-42F4-9582-E6DF52215659 Q28368185-562EA054-FCA5-486A-B491-5ADA55B57065 Q28379547-0CFA08B3-4257-472C-BD9F-87E6213183A9 Q33756241-90819FA0-EAA8-4486-A48A-D63F74BFE529 Q33758399-282597F6-6FD9-4C06-B85F-1D12C52B5EBE Q33979426-A014A9EE-DB5F-47D4-9189-2A37395C4AF3 Q34885043-A343DFB0-99C4-4468-B388-AC661615B535 Q35117545-700D41C9-D5C4-4F4C-8764-FB2BEA0B03CD Q35121233-B9BA105F-E292-4F7E-B74B-C045F2F90E6E Q35124463-804B4078-2CDE-4402-AC36-A3B6EC00121A Q35136634-CA349FE8-A24D-4182-9342-C93BF99A6380 Q35138007-FFA8EA50-7866-4E5F-88E5-0FFC7422E6B3 Q35138023-3CFC0E51-1ACD-419B-81F6-EC7FFA22DC2A Q35271608-B0FAED17-BA47-4B2B-9339-D8BE45D05955 Q35534742-A3BB5039-93E2-4238-A266-C49C5C5B3C40 Q35637864-97B90425-39B7-4DEC-B5F8-46F5FEC84B76 Q35759076-43A4EF28-CDCB-4774-BE2E-D5CA1312938E Q35820407-D79BE5BC-4139-4758-9B1C-F4882B8AC493 Q36505518-91653AE5-70D2-4A2E-8290-B7B89913E84D Q36752580-E77892A0-55D9-453F-93C2-DBA51540217F Q36777850-B315F14B-37B0-4EE8-B9D4-E8A71F3C0E28 Q36911111-FB69F2E2-C526-41B9-A564-BBCCD0D40BCD Q37650115-4FFCC156-BB8F-4B06-AC07-ADA8CB021C43 Q38310341-4B9C307E-8194-48EB-8154-C8485030ADED Q39477095-38BAEB03-948D-4AD7-931F-51D9950C0720 Q39559768-BAC981F2-AD70-461A-8266-039A36F8D9C3 Q39865308-11AC02ED-F5B2-4DB2-85CA-0378C7892619 Q39881225-6299D215-AF72-43CE-8667-4544C20F4457 Q40087066-BC75743C-EF27-444E-B4DB-C22310E99129 Q40284247-A9F1E233-543E-41FA-8AEA-828D0A05CFD8 Q40495778-10C39B74-FFFB-4195-8E89-1AF703FF54F9 Q41005454-DA3551D4-49BC-4B9A-A0CC-8B13E6FACD6A Q41229114-59C082AA-49DB-4B87-8C8F-50081B3A2373 Q41522714-4AB7A84D-9563-4B15-8D90-6E959178F07F Q41646436-FEC6BCE7-D90E-4466-ABCB-A46531D8A7C2 Q44591792-DBED5BE2-E711-468B-AAA9-7E7EF7B5D5ED Q45072518-7F23DE23-2F47-46E6-988C-746B4CFA0527 Q45158747-24DDD1E9-A03D-40C7-B2CD-26B528852AC9 Q52307488-76E8EBA6-19FB-4ED0-8D93-30AB8E388890

P2860

Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.

http://www.wikidata.org/entity/Q35251599

description

1990 nî lūn-bûn

@nan

1990 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1990 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1990年の論文

@ja

1990年学术文章

@wuu

1990年学术文章

@zh-cn

1990年学术文章

@zh-hans

1990年学术文章

@zh-my

1990年学术文章

@zh-sg

1990年學術文章

@yue

name

Effects of dosage, peak and tr ...... rabbit model of endocarditis.

@ast

Effects of dosage, peak and tr ...... rabbit model of endocarditis.

@en

type

label

Effects of dosage, peak and tr ...... rabbit model of endocarditis.

@ast

Effects of dosage, peak and tr ...... rabbit model of endocarditis.

@en

prefLabel

Effects of dosage, peak and tr ...... rabbit model of endocarditis.

@ast

Effects of dosage, peak and tr ...... rabbit model of endocarditis.

@en

P1433

Q35251599-EBF601EE-8C93-4973-B983-45FD27F5E06C

P1476

Q35251599-F624EEF0-0B1A-4B54-B22A-771321D34A47

P2093

Q35251599-8CF0DE77-763A-4215-BBBF-AD08BD99A911

Q35251599-CFD4D9A7-0A08-42BC-8272-D291B6CFE9FC

P2860

Q35251599-0FD54D26-8DE6-4554-9FC6-7884683C17A4

Q35251599-3D4EA2B2-B6B6-46D4-8826-0ADFD7643187

Q35251599-55415848-09EC-44D0-A9EE-8DE0EEA1C522

Q35251599-56875C77-7628-4B0E-8A7A-3CA30023B070

Q35251599-5A603E39-0F19-4DD1-9C0D-9BF5D6036C22

Q35251599-9F2370FE-4490-4FDB-A45E-A55234299377

Q35251599-D1D6D4B5-3F42-4E50-9EED-2E504252AD58

Q35251599-E5614220-7C76-495E-AB34-B3803CC2527D

Q35251599-F20F50EE-70A5-456A-B0DB-E47F8F7A1DF4

Q35251599-F5DC1D82-DF7E-4074-AD00-5B3B168C870A

P304

Q35251599-826A54FA-A6CD-4690-AA9F-87746A97EFA9

P31

Q35251599-40B0765C-7611-4520-A399-411E45BDD481

P356

Q35251599-976ED915-A70D-4CFB-9046-3BEA3DCF679B

P407

Q35251599-B08B8C75-3319-4694-B8F5-96962BBD55C9

P433

Q35251599-3EC5F5FD-00DB-4388-8C45-8A1C9CD6FCD0

P478

Q35251599-1A84BD84-F54D-46C5-9FA6-C165EBA0167D

P577

Q35251599-D7F37843-F070-4CC5-BFE4-9BC6025C9355

P698

Q35251599-9B0E8C0F-4F32-433B-BD52-E67880904C1A

P932

Q35251599-FFD72B39-F8FE-400D-B48A-7BEE82AC7990

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Effects of dosage, peak and tr ...... rabbit model of endocarditis.

@en

P2093

Chambers HF

http://www.w3.org/2001/XMLSchema#string

Kennedy S

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients

Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart.

Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections.

Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations

Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.

Comparative in vitro study of teichomycin A2.

Value of serum tests in combined drug therapy of endocarditis

Teicoplanin: an investigational glycopeptide antibiotic.

Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography.

Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.

P304

510-514

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.34.4.510

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

1990-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

2140496

http://www.w3.org/2001/XMLSchema#string

P932

171634

http://www.w3.org/2001/XMLSchema#string